logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (3)
  • CSV
  • BibTeX
  • EndNote
  • All Results (3)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M,  et al.
2024-06-06 • Antimicrobial Agents and Chemotherapy
2024-06-06 • Antimicrobial Agents and Chemotherapy
Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...
Conference Material
|
Slide Presentation

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO): a mixed-methods, multi-site study

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract

Patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial: PRACTECAL-PRO

Stringer B, Lowton K, Cusinato M, Fielding K, Liverko I,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The TB-PRACTECAL study trialed a shorter, more tolerable regimen of oral drugs than standard of care (SoC) – which can last for up to 20 months and involve both injectab...